BeiGene
ONC
#683
Rank
โ‚น2.483 T
Marketcap
โ‚น21,884
Share price
2.82%
Change (1 day)
82.20%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (ONC) - Cash on Hand

Cash on Hand as of December 2024 : โ‚น224.45 Billion

According to BeiGene 's latest financial reports the company has โ‚น224.45 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

BeiGene - Cash on Hand chart (from 2014 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31โ‚น225.39 B-14.64%
2023-12-31โ‚น264.04 B-29.64%
2022-12-31โ‚น375.25 B-23.81%
2021-12-31โ‚น492.55 B44.82%
2020-12-31โ‚น340.12 B385.33%
2019-12-31โ‚น70.08 B-43.74%
2018-12-31โ‚น124.56 B132.93%
2017-12-31โ‚น53.47 B113.74%
2016-12-31โ‚น25.01 B274.66%
2015-12-31โ‚น6.67 B137.33%
2014-12-31โ‚น2.81 B1060.04%
2013-12-31โ‚น0.24 B

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
โ‚น1.40 B-99.38%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น36.90 B-83.56%๐Ÿ‡บ๐Ÿ‡ธ USA